We continue to experience strong demand for AJOVY® (fremanezumab-vfrm) injection since launching in September 2018, as evidenced by market share and utilization. Acceptance by patients and healthcare providers lends an important voice to our ongoing discussions with payers.
Currently, we estimate more than 75 percent of commercial patients have coverage for AJOVY. This includes coverage with two large national PBMs, CVS Caremark, and ESI. Effective April 1, AJOVY moved from non-preferred to preferred on Express Scripts’ National Preferred & Basic Commercial Formularies. Also effective on April 1, AJOVY moved from not covered to preferred on Cigna’s Commercial Standard Formulary. This is good news for patients as it means more lives are covered for this important treatment. Discussions with numerous national and regional payers to provide formulary coverage continue.
Finally, AJOVY will move to non-preferred on Prime’s Accord Commercial Formulary and will be not covered on Prime’s Net Results Commercial Formulary.
We are committed to increasing access to AJOVY, and commercially insured patients – regardless of formulary decisions – may still use the Savings Offer for AJOVY, allowing them to pay as little as $0. Note that patients eligible for government-sponsored coverage are not eligible for the Savings Offer. Teva’s Shared Solutions® program is also committed to helping patients gain access to AJOVY with a team available to research and understand patients’ coverage and benefits.
We are confident in the value AJOVY brings to the healthcare system, as well as the strategic decisions made when establishing the price for AJOVY.
INDICATION
AJOVY® is indicated for the preventive treatment of migraine in adults.
IMPORTANT SAFETY INFORMATION
Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.
Adverse Reactions: The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.
Please click here for full Prescribing Information for AJOVY® (fremanezumab-vfrm) injection.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding AJOVY, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2018, including the sections thereof captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
###
IR Contacts |
United States |
Kevin C. Mannix |
(215) 591-8912 |
|
Israel |
Ran Meir |
(215) 591-3033 |
|
|
|
|
PR Contacts |
United States |
Doris Saltkill |
(913) 777-3343 |
|
Israel |
Yonatan Beker |
972 (54) 888 5898 |